insitro

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: @insitro CEO @DaphneKoller on how AI is hitting “escape velocity” for finding causal targets for disease and speeding up drug development. Full video: biotechtv.com/post/insitro-j…

Today we announced Joe Hand as insitro’s Chief People Officer. Joe brings a wealth of experience in scaling life sciences organizations, including serving as CHRO and Executive Committee member at Celgene, where he led global talent strategy through significant growth and major transactions. As we advance our AI-driven discovery platform and move programs toward the clinic, Joe will lead our global people strategy to support insitro’s next phase of growth. Welcome to the team, Joe! Read more: insitro.com/news/insitro-a…

insitro’s David Lloyd reported at the @KeystoneSymp the first-ever genome-wide association study (GWAS) of brown adipose tissue – and a differentiated target with anti-obesity effects, the modulation of which reduced body weight 15% and fat mass 25% in preclinical models while preserving lean tissue. Brown fat was genetically inaccessible for decades – not for lack of interest, but because the tissue resists measurement at scale. ML-derived phenotypes from 70K MRIs resolved that. The weight loss comes from burning more, not merely eating less. This work suggests a path to differentiated obesity treatments and illustrates a broader shift in human genetics. We've shown that phenotype quality can transcend data limitations, and AI is helping us make that leap. Learn more: insitro.com/news/insitro-c…

“We want to build an engine that brings transformative medicines to patients,” says insitro founder and CEO @DaphneKoller in conversation with @BiotechTV during #JPM26. Daphne sat down with Ryan Flinn for SF Health Week to discuss how AI is accelerating drug discovery at insitro and how models designed to work in partnership with scientists are helping turn complex data into meaningful therapeutic insights.

Today marks a major milestone for insitro with the acquisition of CombinAbleAI and the launch of TherML™, our unified, modality-agnostic therapeutic design platform. TherML expands our AI-enabled system across small molecules, oligonucleotides, and complex biologics, integrating physics-informed design so potency and developability are optimized together from the start. We’re excited to welcome the CombinAbleAI team in Israel as insitro’s newest R&D center and take this next step toward more predictable, scalable, and accelerated drug discovery. 🔗 insitro.com/news/combinabl… Dive into TherML: insitro.com/news/introduci… #Biotech #DrugDiscovery #AI

insitro Founder and CEO @DaphneKoller presents at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12 at 4 p.m. PT – providing updates on our AI-enabled discovery platform and therapeutic programs. insitro leaders will also participate in key Healthcare Week discussions: → Sunday: Daphne joins the @LongwoodLeaders SF CEO panel “Identifying Next-Generation Therapeutics.” → Wednesday: CFO/CBO @mmrozenman joins the “Transaction to Transformation” panel at the @KPMG + @goodwinlaw Symposium. We look forward to engaging with the investment community, partners, and industry leaders throughout the week. insitro.com/news/insitro-t… #JPM2026 #Biotech #DrugDiscovery #AI

We are absolutely thrilled to share that insitro’s POSH platform – integrating pooled CRISPR screening and self-supervised deep learning – has been validated in new research published today in Nature Communications. We built a new kind of automated robotic lab to map gene function at scale – free from human bias. By capturing subtle, holistic changes rather than isolated metrics, the platform reveals therapeutic targets that conventional methods systematically miss. As our CEO @DaphneKoller notes, “Biology doesn't organize itself according to the features we've learned to measure.” Congrats to the paper’s authors for their work on this transformative research. Step inside the world of POSH in our new video below. Paper 🔗 nature.com/articles/s4146… #AI #DrugDiscovery #Biotech #CausalBiology

Is the next AI breakthrough a better chatbot — or a therapy we could not develop before? insitro CEO @DaphneKoller joins @FortuneMagazine #FortuneBrainstormAI on Mon, Dec. 8 for “The New AI Power Shift” with @AnimaAnandkumar and @RaquelUrtasun. Daphne will discuss how to design AI that is rigorous enough to discover medicines that actually work — not just generate plausible outputs — and how the shift from lab research to large-scale deployment is reshaping scientific discovery and industry leadership. #DrugDiscovery #Tech #AI conferences.fortune.com/event/brainsto…

insitro’s @samuel_sances will be at the Intl. Symposium on ALS/MND 12/7 to present work w/ Bristol Myers Squibb. Using #ML on 200+ patient-derived motor neuron lines, we found genes that rescue cellular function—reversing TDP-43 pathology & restoring STMN2. symposium.mndassociation.org #DrugDiscovery #ALS

insitro is proud to welcome Stephen Hitchcock (former Takeda CSO) and @VijayPande (VZVC co-founder, ex-insitro Board) as scientific advisors. Their focus: bridging the gap between AI-predicted targets and the medicinal chemistry required to advance candidates into clinical trials. insitro.com/news/insitro-a…

Will #AI usher in a new era of rapid drug discovery? In this episode of JAMA+ AI Conversations, Editor in Chief Roy Perlis, MD, MSc, interviews Ajamete Kaykas, PhD, Chief eXploration Officer at insitro. Listen now: ja.ma/4qWb0PC

For a primer in advance of Emily's #ML4H keynote on 12/2, check out the she Emily gave last week at the @broadinstitute: "Beyond Prediction: Causal Validity in ML-Driven Drug Discovery & Health Monitoring" -- youtube.com/watch?v=eTXBaE… #AI #ML #drugdiscovery #NeurIPS2025

Heading to #NeurIPS2025? Don't miss @insitro’s Emily Fox at the #ML4H Symposium. She’ll discuss the shift from correlative prediction to causal validity, moving AI from pattern recognition to decision-ready science. 🗓 Tue, Dec 2 @ 4:45 PM PT 📍 ML4H Symposium 🔗 ml4health.github.io/2025/ #CausalAI #DrugDiscovery

From genetic correlation to validated mechanism, and new therapeutic candidate. @insitro's MASLD program (CTRO-1013) targeting IRS1 was recently named a Poster of Distinction at #AASLD2025. We used AI on multimodal data from 263K people to find the target, now validated & advancing to IND-enabling studies. Congrats to the team driving this work! Read our article to learn more: insitro.com/news/revealing… #DrugDiscovery #AIinMedicine #MASLD

We’re excited to announce a new collaboration with @EliLillyandCo to build next-gen #machinelearning models for small molecule design. Through this partnership, we’ll train advanced #ML models on Lilly’s rich preclinical dataset to overcome a longstanding problem in drug discovery. It will be available to insitro and our partners, Lilly and their partners, including members of Lilly TuneLab, a new platform designed to empower biotechs with cutting-edge ML tools to transform medicine discovery.  This model has the potential to give researchers the ability to zero in on drug-like chemical structures at the earliest stages. Read more: insitro.com/news/insitro-p…

Gabriel blends biology & #ML to drive small molecule #drugdevelopment. From melanoma research to a Master’s at UCL to presenting insitro’s KinDEL dataset @ ICML, his career advances drug discovery w/ scalable data & predictive modeling. Read Gabriel's Meet the insitrocyte below. arxiv.org/abs/2410.08938

7️⃣ years using #machinelearning and data at scale to understand disease better and bring medicines to patients who can benefit most. Cheers to our team, our partners, and the belief that better is always possible. ✨

🎙️Tune in to Episode 197 of #TheGeneticsPodcast 🚀 This week, we’re joined by Heiko Runz, medical geneticist and VP of Neuroscience at @insitro . Listen in to hear about @heikorunz's path from academia to industry, his role in developing tofersen for SOD1 ALS, how he integrates genomic data across biobanks to uncover novel drug targets, and his use of large-scale cell-based phenotyping to study mechanisms in ALS and other neurological diseases. Available here👇 🎧 pod.fo/e/3019d8 📽️ youtu.be/_qGbl1Z2HDE #genetics #SanoGenetics #genomics #PrecisionMedicine

“You can use AI for good, like making better medicines.” @DaphneKoller joins @FortuneMagazine’s #LeadershipNext to talk about #AI scenarios, preparing for careers in the AI era as well as insitro’s next chapter and the value of connecting the dots. Listen below. ⬇️